Logo

Orion Signs a Collaborative Agreement with Newel Health to Develop ODD-403 for Chronic Pain

Share this

Orion Signs a Collaborative Agreement with Newel Health to Develop ODD-403 for Chronic Pain

Shots:

  • Orion Corporation and Newel Helth joined forces to enhance the development of Orion’s ODD-403 (Rohkea) as a digital therapeutic for the treatment of patients suffering from chronic pain or fear of movement & re-injury
  • Under the terms of the agreement, Newel will receive the exclusive rights to develop, manufacture, and commercialize ODD-403 globally whereas Orion will receive milestones payments plus royalties from the sales of the product
  • ODD-403 is a software-based medical device built for VR devices to deliver an immersive gamified therapeutic treatment program for patients suffering from chronic pain

Ref: Orion | Image: Orion

Related News:- Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions